ZEISS completes its search for new leadership in the Medical Technology segment
"With Bronwyn Brophy O’Connor, we are pleased to have found a successor who has excelled internationally"
Advertisement
The Supervisory Board of Carl Zeiss AG has appointed Bronwyn Brophy O’Connor as the new Executive Board Member of Carl Zeiss AG responsible for the medical technology segment. At the same time, the Supervisory Board of the publicly listed Carl Zeiss Meditec AG has appointed her to its Management Board as CEO. Bronwyn Brophy O’Connor is currently CEO of the Vitrolife Group, which is headquartered in Gothenburg and listed on the NASDAQ Stockholm in Sweden. She previously held senior positions at multinational medical technology companies, such as Thermo Fisher Scientific, Medtronic, and Johnson & Johnson, and worked in the U.K., Ireland, Switzerland, Spain, and the U.S., among other countries. Her responsibilities have included strategy development, turnarounds, geographic expansion into American and Asian markets, mergers and acquisitions, as well as research and development programs, such as for the diagnosis of autoimmune diseases and the adoption of innovative therapies. In these roles, she had financial responsibility for up to eight billion euros.
Bronwyn Brophy O’Connor, currently CEO of the Vitrolife Group in Sweden, will become the new Executive Board Member of Carl Zeiss AG responsible for the Medical Technology segment and the new CEO of the publicly listed Carl Zeiss Meditec AG.
Carl Zeiss AG
This appointment concludes the selection process to fill the position of CEO of Carl Zeiss Meditec AG on a long-term basis. The President and CEO of Carl Zeiss AG, Andreas Pecher, took on this position on an interim basis in January 2026. Bronwyn Brophy O’Connor will take up her role at the ZEISS Medical Technology segment as soon as possible. The exact start date is subject to current negotiations and will be communicated at a later time. Until then, Andreas Pecher will continue to act as interim CEO of Carl Zeiss Meditec AG.
“With Bronwyn Brophy O’Connor, we are pleased to have found a successor who has excelled internationally. She has over 25 years of professional experience in medical technology and life sciences and, with her exceptional capabilities, will play a key role in shaping the ongoing realignment of ZEISS Medical Technology,” said Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG. “We wish her a great start and all the best for her new position at ZEISS.”
Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG, added, “We would like to thank Andreas Pecher for his outstanding commitment and excellent work in his temporary additional role as interim head of the segment and CEO of Carl Zeiss Meditec AG. In a short time, Andreas Pecher laid the critical groundwork for the future success of ZEISS Medical Technology.”
Andreas Pecher, President and CEO of Carl Zeiss AG, said, “We are pleased that we have found a proven expert in Bronwyn Brophy O’Connor with her many years of experience in medical technology, which is a strategically important market for ZEISS. She will bring important momentum to Carl Zeiss Meditec AG and the ZEISS Group. I would like to thank our team at the ZEISS Medical Technology segment for their trust and strong commitment in the past months, and I am looking forward to once again focusing exclusively on my role as President and CEO of the ZEISS Group as soon as possible.”
The Executive Board of Carl Zeiss AG will consist of the following members: Andreas Pecher (President and CEO), Stefan Müller (CFO), Bronwyn Brophy O’Connor (Head of the ZEISS Medical Technology segment), Sven Hermann (Head of the ZEISS Consumer Markets segment), Dr. Frank Rohmund (Head of the ZEISS Semiconductor Manufacturing Technology segment), and Dr. Marc Wawerla (Head of the ZEISS Industrial Quality & Research segment).
The Management Board of Carl Zeiss Meditec AG will consist of Bronwyn Brophy O’Connor (CEO) and Justus Wehmer (CFO).
Other news from the department people
